Turn Therapeutics (TTRX) FDA Approvals $8.12 -0.44 (-5.09%) As of 12:51 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Turn Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Turn Therapeutics (TTRX). Over the past two years, Turn Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as GX-03. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. GX-03 FDA Regulatory Timeline and Events GX-03 is a drug developed by Turn Therapeutics for the following indication: Atopic Dermatitis Treatment. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - August 20,2026Publication Drug: GX-03Announced Date: August 20, 2026Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics Inc. announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease.Read AnnouncementProvided Update - July 7,2026Provided Update Phase 2Drug: GX-03Announced Date: July 7, 2026Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics, Inc announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis.AI SummaryTurn Therapeutics said it finished a broad interim review of its adaptive Phase 2 trial testing GX-03 for atopic dermatitis. The company said the analysis showed meaningful benefits across a wider range of patients, supporting a plan to study people across the full range of disease severity measured by EASI. The review also helped the company choose the best patient group, endpoint plan, disease grouping, and statistical method for the next part of the trial. For Stage 2, Turn Therapeutics plans to use the FDA-recognized Hochberg multiple testing procedure. This will let the study test several efficacy endpoints and still look for statistical significance, instead of relying on only one primary endpoint. The company said the final Stage 2 design is based on the interim data and is meant to strengthen the ongoing Phase 2 program.Read AnnouncementInterim Analysis - June 1,2026Interim Analysis Phase 2Drug: GX-03Announced Date: June 1, 2026Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics Inc announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis.AI SummaryTurn Therapeutics Inc. reported interim results from the first 50 patients in its ongoing Phase 2 trial of GX-03 for adults with moderate-to-severe atopic dermatitis. The study is randomized, double-blind, and vehicle-controlled. After four weeks, 92.6% of patients treated with GX-03 reached EASI-50, meaning at least a 50% drop in eczema severity. In the same period, 70.4% reached EASI-75 and 44.4% reached EASI-90. By eight weeks, 51.9% reached EASI-90, showing very strong skin improvement over time. No treatment-related serious side effects were seen in either group, and there were no treatment-related tolerability problems or dropouts. Based on the early data, the company refined its enrollment criteria, endpoint plan, and overall trial strategy. Turn Therapeutics said GX-03 continued to show a favorable safety and tolerability profile as the trial moves forward.Read AnnouncementPublication - May 27,2026Publication Drug: GX-03Announced Date: May 27, 2026Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics Inc. announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36–associated inflammatory environment.AI SummaryTurn Therapeutics Inc. announced the publication of a peer-reviewed study in the Journal of Dermatological Treatment on its lead program, GX-03. The research examined how an extended-release topical polyhexanide treatment worked in a mouse model of Staphylococcus aureus-induced dermatitis linked to IL-36, a marker tied to inflammation. The study, titled “Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression,” was co-authored by company CEO Bradley Burnam and Dr. Stephen Bresnick. Turn Therapeutics said the paper is the first in a planned series that will look at GX-03’s biological and clinical effects. The company also noted that a follow-up manuscript is already under review and will focus on how the treatment works at a deeper mechanistic level.Read AnnouncementProvided Update - November 11,2025Provided Update Drug: GX-03Announced Date: November 11, 2025Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics announced it has been named as one of the "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine.AI SummaryTurn Therapeutics announced it was named one of the "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine. The company said its GX-03 topical technology earned the recognition as a top innovation in eczema care. CEO Bradley Burnam said IL-36 plays a key role in the inflammation behind atopic dermatitis, eczema and psoriasis. GX-03 is described as the first topical to target IL-36, potentially offering an alternative to systemic drugs and injectables. Company studies showed GX-03 can inhibit IL-36 alpha, IL-36 gamma, IL-31 and IL-4. Patient Care Online is an educational resource for office-based clinicians. Turn said it is advancing its pipeline and expects topline data from its lead severe eczema program in early 2026, aiming to bring a new topical option to patients in need.Read Announcement Turn Therapeutics FDA Events - Frequently Asked Questions Has Turn Therapeutics received FDA approval? As of now, Turn Therapeutics (TTRX) has not received any FDA approvals for its therapy in the last two years. What drugs has Turn Therapeutics submitted to the FDA? In the past two years, Turn Therapeutics (TTRX) has reported FDA regulatory activity for GX-03. What is the most recent FDA event for Turn Therapeutics? The most recent FDA-related event for Turn Therapeutics occurred on August 20, 2026, involving GX-03. The update was categorized as "Publication," with the company reporting: "Turn Therapeutics Inc. announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease." What conditions do Turn Therapeutics' current drugs treat? Currently, Turn Therapeutics has one therapy (GX-03) targeting the following condition: Atopic Dermatitis Treatment. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsEikon Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA EventsVeru FDA EventsMedtronic FDA EventsAclaris Therapeutics FDA EventsBioVie FDA EventsBioLineRx FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Amphastar Pharmaceuticals FDA Events Compass Pathways FDA Events Spyglass Pharma FDA Events Harrow FDA Events Theravance Biopharma FDA Events Ardelyx FDA Events Achieve Life Sciences FDA Events Cybin FDA Events Ovid Therapeutics FDA Events Aquestive Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:TTRX last updated on 8/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turn Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - August 20,2026Publication Drug: GX-03Announced Date: August 20, 2026Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics Inc. announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease.Read Announcement
Provided Update - July 7,2026Provided Update Phase 2Drug: GX-03Announced Date: July 7, 2026Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics, Inc announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis.AI SummaryTurn Therapeutics said it finished a broad interim review of its adaptive Phase 2 trial testing GX-03 for atopic dermatitis. The company said the analysis showed meaningful benefits across a wider range of patients, supporting a plan to study people across the full range of disease severity measured by EASI. The review also helped the company choose the best patient group, endpoint plan, disease grouping, and statistical method for the next part of the trial. For Stage 2, Turn Therapeutics plans to use the FDA-recognized Hochberg multiple testing procedure. This will let the study test several efficacy endpoints and still look for statistical significance, instead of relying on only one primary endpoint. The company said the final Stage 2 design is based on the interim data and is meant to strengthen the ongoing Phase 2 program.Read Announcement
Interim Analysis - June 1,2026Interim Analysis Phase 2Drug: GX-03Announced Date: June 1, 2026Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics Inc announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis.AI SummaryTurn Therapeutics Inc. reported interim results from the first 50 patients in its ongoing Phase 2 trial of GX-03 for adults with moderate-to-severe atopic dermatitis. The study is randomized, double-blind, and vehicle-controlled. After four weeks, 92.6% of patients treated with GX-03 reached EASI-50, meaning at least a 50% drop in eczema severity. In the same period, 70.4% reached EASI-75 and 44.4% reached EASI-90. By eight weeks, 51.9% reached EASI-90, showing very strong skin improvement over time. No treatment-related serious side effects were seen in either group, and there were no treatment-related tolerability problems or dropouts. Based on the early data, the company refined its enrollment criteria, endpoint plan, and overall trial strategy. Turn Therapeutics said GX-03 continued to show a favorable safety and tolerability profile as the trial moves forward.Read Announcement
Publication - May 27,2026Publication Drug: GX-03Announced Date: May 27, 2026Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics Inc. announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36–associated inflammatory environment.AI SummaryTurn Therapeutics Inc. announced the publication of a peer-reviewed study in the Journal of Dermatological Treatment on its lead program, GX-03. The research examined how an extended-release topical polyhexanide treatment worked in a mouse model of Staphylococcus aureus-induced dermatitis linked to IL-36, a marker tied to inflammation. The study, titled “Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression,” was co-authored by company CEO Bradley Burnam and Dr. Stephen Bresnick. Turn Therapeutics said the paper is the first in a planned series that will look at GX-03’s biological and clinical effects. The company also noted that a follow-up manuscript is already under review and will focus on how the treatment works at a deeper mechanistic level.Read Announcement
Provided Update - November 11,2025Provided Update Drug: GX-03Announced Date: November 11, 2025Indication: Atopic Dermatitis TreatmentAnnouncementTurn Therapeutics announced it has been named as one of the "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine.AI SummaryTurn Therapeutics announced it was named one of the "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine. The company said its GX-03 topical technology earned the recognition as a top innovation in eczema care. CEO Bradley Burnam said IL-36 plays a key role in the inflammation behind atopic dermatitis, eczema and psoriasis. GX-03 is described as the first topical to target IL-36, potentially offering an alternative to systemic drugs and injectables. Company studies showed GX-03 can inhibit IL-36 alpha, IL-36 gamma, IL-31 and IL-4. Patient Care Online is an educational resource for office-based clinicians. Turn said it is advancing its pipeline and expects topline data from its lead severe eczema program in early 2026, aiming to bring a new topical option to patients in need.Read Announcement